Oramed Pharm (ORMP) Price & Analysis

Compare

523 Followers

ORMP Stock Chart & Stats

$2.91

-$0.04(-1.65%)

At close: Jan 08 4:00 PM EST

$2.91

-$0.04(-1.65%)

Day’s Range― - ―

52-Week Range$1.82 - $3.54

Previous CloseN/A

Volume63.61K

Average Volume (3M)210.74K

Market Cap

$136.52M

Enterprise Value$0.00

Total Cash (Recent Filing)$134.69M

Total Debt (Recent Filing)$860.00K

Price to Earnings (P/E)3.4

Beta0.65

Next Earnings

Jul 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding39,802,456

10 Day Avg. Volume339,860

30 Day Avg. Volume210,739

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-11.72

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

InvestmentThe joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.

Joint VentureOramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.

Bears Say

Clinical EfficacyThe candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.

Oramed Pharm News

Oramed and Lifeward sign strategic transaction

Oramed (ORMP) and Lifeward (LFWD) signed binding agreements for a strategic transaction between Oramed, Lifeward and a certain...

20h ago

LFWD

ORMP

Oramed receives $18M payment from Scilex Holdings

Oramed (ORMP) Pharmaceuticals announced it has received an $18M payment from Scilex Holdings, representing full satisfaction of obligations...

7d ago

ORMP

Oramed declares cash dividend payment of 25c per share

Oramed’s (ORMP) Board of Directors has approved a cash dividend payment of 25c per share to reward shareholders....

7d ago

ORMP

Oramed Pharm Announces Dividend After Scilex Payment Gain

Oramed Pharm ( ($ORMP) ) has provided an update. On January 7, 2026, Oramed Pharmaceuticals reported receiving an...

7d ago

ORMP

Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation

Oramed Pharm ( ($ORMP) ) just unveiled an update. On December 31, 2025, Oramed Pharmaceuticals Inc. announced that...

13d ago

ORMP

Oramed Pharm Completes Warrant Sale, Boosting Liquidity

An announcement from Oramed Pharm ( ($ORMP) ) is now available. On July 22, 2025, Oramed Pharmaceuticals Inc....

14d ago

ORMP

Oramed Pharm Declares Dividend Amidst Takeover Defense

Oramed Pharm ( ($ORMP) ) has provided an announcement. On November 16, 2025, Oramed Pharmaceuticals’ Board of Directors...

2M ago

ORMP

Oramed declares dividend distribution of common stock purchase rights

Oramed (ORMP) has unanimously adopted a Rights Agreement dated November 17 by and between the company and its...

2M ago

ORMP

Oramed Pharm Repurchases Shares, Ends Joint Venture

Oramed Pharm ( ($ORMP) ) has shared an announcement. On October 20, 2025, Oramed Pharmaceuticals repurchased and retired...

3M ago

ORMP

Oramed Pharm Completes Warrant Repurchase Agreement

Oramed Pharm ( ($ORMP) ) has provided an announcement. On September 30, 2025, Oramed Pharmaceuticals Inc. completed the...

3M ago

ORMP

Scilex completes first tranche of Oramed warrant repurchase

Scilex Holding Company (SCLX) repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price...

3M ago

ORMP

SCLX

Oramed Pharm Approves Stock Incentive Plan Amendment

An update from Oramed Pharm ( ($ORMP) ) is now available. On August 19, 2025, Oramed Pharmaceuticals Inc....

5M ago

ORMP

Oramed Pharm and Scilex Finalize Option Agreement

Oramed Pharm ( ($ORMP) ) just unveiled an announcement. Oramed Pharmaceuticals Inc. entered into a Securities Purchase Agreement...

6M ago

ORMP

Oramed Pharm Extends Stock Buyback Program

Oramed Pharm ( ($ORMP) ) has issued an announcement. On May 21, 2025, Oramed Pharmaceuticals Inc. announced a...

8M ago

ORMP

ORMP FAQ

What was Oramed Pharmaceuticals’s price range in the past 12 months?

Oramed Pharmaceuticals lowest stock price was $1.82 and its highest was $3.54 in the past 12 months.

What is Oramed Pharmaceuticals’s market cap?

Oramed Pharmaceuticals’s market cap is $136.52M.

When is Oramed Pharmaceuticals’s upcoming earnings report date?

Oramed Pharmaceuticals’s upcoming earnings report date is Jul 15, 2026 which is in 182 days.

How were Oramed Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Oramed Pharmaceuticals overvalued?

According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Oramed Pharmaceuticals pay dividends?

Oramed Pharmaceuticals does not currently pay dividends.

What is Oramed Pharmaceuticals’s EPS estimate?

Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oramed Pharmaceuticals have?

Oramed Pharmaceuticals has 39,802,456 shares outstanding.

What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Oramed Pharmaceuticals?

Currently, no hedge funds are holding shares in ORMP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oramed Pharm Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

24.38%

Trailing 12-Months

Asset Growth

33.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.